Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Community analysis and co-occurrence patterns in airway microbial communities during health and disease.

Einarsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, Elborn JS.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00128-2017. doi: 10.1183/23120541.00128-2017. eCollection 2019 Jul.

2.

Tackling bias in clinical trials.

van Koningsbruggen-Rietschel S, Downey DG.

J Cyst Fibros. 2019 Jul;18(4):445-446. doi: 10.1016/j.jcf.2019.06.001. No abstract available.

PMID:
31230796
3.

Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

Sherrard LJ, Einarsson GG, Johnston E, O'Neill K, McIlreavey L, McGrath SJ, Gilpin DF, Downey DG, Reid A, McElvaney NG, Boucher RC, Muhlebach MS, Elborn JS, Tunney MM.

J Cyst Fibros. 2019 Mar 21. pii: S1569-1993(19)30052-9. doi: 10.1016/j.jcf.2019.02.012. [Epub ahead of print]

PMID:
30905581
4.

Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus.

Kirkwood ZI, Millar BC, Downey DG, Moore JE.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):358-360. doi: 10.4103/ijmy.ijmy_142_18.

5.

Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report.

Addy C, Doran G, Jones AL, Wright G, Caskey S, Downey DG.

BMC Pulm Med. 2018 Nov 19;18(1):170. doi: 10.1186/s12890-018-0732-3.

6.

Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age.

Shteinberg M, Lulu AB, Downey DG, Blumenfeld Z, Rousset-Jablonski C, Perceval M, Colombo A, Stein N, Livnat G, Gur M, Bentur L, Mussaffi H, Blau H, Sarouk I, Dagan A, Kerem E, Aviram M, Picard E, Aliberti S, Álvarez A, Miranda JP, Polverino E, Durieu I, Stuart Elborn J, Cohen-Cymberknoh M.

J Cyst Fibros. 2019 Jul;18(4):525-529. doi: 10.1016/j.jcf.2018.10.009. Epub 2018 Oct 23.

PMID:
30366850
7.

Theratyping in cystic fibrosis.

Crawford KJ, Downey DG.

Curr Opin Pulm Med. 2018 Nov;24(6):612-617. doi: 10.1097/MCP.0000000000000521. Review.

PMID:
30124524
8.

Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.

Millar BC, Rendall JC, Downey DG, Moore JE.

J Clin Pharm Ther. 2018 Dec;43(6):836-843. doi: 10.1111/jcpt.12722. Epub 2018 Jun 29.

PMID:
29959786
9.

Antimicrobial effect of dimethyl sulfoxide and N, N-Dimethylformamide on Mycobacterium abscessus: Implications for antimicrobial susceptibility testing.

Kirkwood ZI, Millar BC, Downey DG, Moore JE.

Int J Mycobacteriol. 2018 Apr-Jun;7(2):134-136. doi: 10.4103/ijmy.ijmy_35_18.

10.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

11.

INCREASING BURDEN OF ANTIMICROBIAL RESISTANCE IN PSEUDOMONAS AERUGINOSA FROM ADULT PATIENTS WITH CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: THEN AND NOW.

Gramegna A, Moore JE, McCaughan J, Millar BC, Ewing J, Elborn JS, Blasi F, Downey DG.

Ulster Med J. 2018 May;87(2):129-130. Epub 2018 May 30. No abstract available.

12.

In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.

Gramegna A, Millar BC, Blasi F, Elborn JS, Downey DG, Moore JE.

J Glob Antimicrob Resist. 2018 Sep;14:224-227. doi: 10.1016/j.jgar.2018.03.002. Epub 2018 Mar 17.

PMID:
29559421
13.

The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice.

Boyle M, Moore JE, Whitehouse JL, Bilton D, Downey DG.

Med Mycol. 2019 Feb 1;57(2):155-160. doi: 10.1093/mmy/myy014.

PMID:
29554296
14.

Laboratory Diagnosis and Characterization of Fungal Disease in Patients with Cystic Fibrosis (CF): A Survey of Current UK Practice in a Cohort of Clinical Microbiology Laboratories.

Boyle M, Moore JE, Whitehouse JL, Bilton D, Downey DG.

Mycopathologia. 2018 Aug;183(4):723-729. doi: 10.1007/s11046-018-0251-z. Epub 2018 Mar 2.

PMID:
29500636
15.

Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis.

O'Neill K, Bradley JM, Reid A, Downey DG, Rendall J, McCaughan J, Moore JE, Tunney MM, Elborn JS.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701704. doi: 10.1183/13993003.01704-2017. Print 2018 Feb. No abstract available.

PMID:
29386349
16.

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.

Millar BC, McCaughan J, Rendall JC, Downey DG, Moore JE.

J Clin Pharm Ther. 2018 Feb;43(1):92-100. doi: 10.1111/jcpt.12616. Epub 2017 Sep 22.

PMID:
29293275
17.

Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His.

Shteinberg M, Downey DG, Beattie D, McCaughan J, Reid A, Stein N, Elborn JS.

ERJ Open Res. 2017 Mar 31;3(1). pii: 00056-2016. doi: 10.1183/23120541.00056-2016. eCollection 2017 Jan.

18.

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis.

Vallières E, Tumelty K, Tunney MM, Hannah R, Hewitt O, Elborn JS, Downey DG.

Eur Respir J. 2017 Apr 12;49(4). pii: 1600851. doi: 10.1183/13993003.00851-2016. Print 2017 Apr. No abstract available.

19.

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.

Plant BJ, Downey DG, Eustace JA, Gunaratnam C, Haworth CS, Jones AM, McKone EF, Peckham DG, Ketchell RI, Bilton D.

J Cyst Fibros. 2017 Nov;16(6):695-701. doi: 10.1016/j.jcf.2017.02.006. Epub 2017 Apr 6.

20.

Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.

O'Neill K, Moran F, Tunney MM, Elborn JS, Bradbury I, Downey DG, Rendall J, Bradley JM.

BMJ Open Respir Res. 2017 Jan 12;4(1):e000168. doi: 10.1136/bmjresp-2016-000168. eCollection 2017.

21.

MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Vallières E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG.

ERJ Open Res. 2016 Mar 15;2(1). pii: 00064-2015. eCollection 2016 Jan.

22.

Closed circuit rebreathing to achieve inert gas wash-in for multiple breath wash-out.

Horsley AR, O'Neill K, Downey DG, Elborn JS, Bell NJ, Smith J, Owers-Bradley J.

ERJ Open Res. 2016 Jan 22;2(1). pii: 00042-2015. eCollection 2016 Jan.

23.

A change in behaviour: getting the balance right for research and policy.

O'Sullivan M, Ryan C, Downey DG, Hughes CM.

Int J Clin Pharm. 2016 Oct;38(5):1027-31. doi: 10.1007/s11096-016-0351-0.

PMID:
27473708
24.

Lung Clearance Index in Adults and Children With Cystic Fibrosis.

O'Neill K, Tunney MM, Johnston E, Rowan S, Downey DG, Rendall J, Reid A, Bradbury I, Elborn JS, Bradley JM.

Chest. 2016 Dec;150(6):1323-1332. doi: 10.1016/j.chest.2016.06.029. Epub 2016 Jul 6.

PMID:
27395423
25.

How reliable are cough swabs for the detection of Pseudomonas aeruginosa in adult patients with cystic fibrosis?

Moore JE, McCaughan J, McNeilly J, Rendall JC, Downey DG.

Br J Biomed Sci. 2015;72(4):206. No abstract available.

PMID:
26738405
26.

Pharmacists' perspectives on monitoring adherence to treatment in Cystic Fibrosis.

Mooney K, Ryan C, Downey DG.

Int J Clin Pharm. 2016 Apr;38(2):296-302. doi: 10.1007/s11096-015-0239-4. Epub 2015 Dec 29.

PMID:
26715548
28.

Pseudomonas aeruginosa displays an altered phenotype in vitro when grown in the presence of mannitol.

Moore JE, Rendall JC, Downey DG.

Br J Biomed Sci. 2015;72(3):115-9.

PMID:
26510267
29.

Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis Outcomes.

Shteinberg M, Rivlin J, Gur M, Konopnicki M, Stein N, Tunney MM, Elborn JS, Downey DG, Johnston E, Shalom H, Levy A.

Lung. 2015 Dec;193(6):1017-21. doi: 10.1007/s00408-015-9801-z. Epub 2015 Sep 14.

PMID:
26370551
30.

Survival dynamics of cystic fibrosis-related Gram-negative bacterial pathogens (Pseudomonas aeruginosa and Burkholderia cenocepacia) in Dead Sea and Atlantic Ocean waters.

Shteinberg M, Kis-Papo T, Millar BC, Rendall JC, Downey DG, Elborn JS, Moore JE.

J Water Health. 2015 Sep;13(3):773-6. doi: 10.2166/wh.2015.157.

PMID:
26322762
31.

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis.

Kenny SL, Shaw TD, Downey DG, Moore JE, Rendall JC, Elborn JS.

BMJ Open Respir Res. 2014 Apr 23;1(1):e000021. doi: 10.1136/bmjresp-2014-000021. eCollection 2014.

32.

Do veterinary antibiotics have efficacy against highly resistant Gram-negative pathogens from patients with cystic fibrosis?

Moore JE, Alcorn M, Ara W, Millar BC, McCaughan J, Rendall JC, McNeilly J, Kuribayashi T, Yamamoto S, Matsuda M, Goldsmith CE, Elborn JS, Downey DG.

Int J Antimicrob Agents. 2015 Jan;45(1):93-5. doi: 10.1016/j.ijantimicag.2014.08.003. Epub 2014 Sep 6. No abstract available.

PMID:
25245210
33.

Current pregnancy outcomes in women with cystic fibrosis.

Burden C, Ion R, Chung Y, Henry A, Downey DG, Trinder J.

Eur J Obstet Gynecol Reprod Biol. 2012 Oct;164(2):142-5. doi: 10.1016/j.ejogrb.2012.06.013. Epub 2012 Jul 9.

PMID:
22784584
34.

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.

Rao P, McCaughan J, McCalmont M, Goldsmith CE, Hall V, Millar BC, McCann MA, Downey DG, Rendall JC, Elborn JS, Moore JE.

J Cyst Fibros. 2012 Jul;11(4):349-52. doi: 10.1016/j.jcf.2012.01.002. Epub 2012 Feb 9. No abstract available.

35.

Thoracic ultrasound for pleural effusion: delays and cost associated with departmental scanning.

Bateman K, Downey DG, Teare T.

Respir Med. 2010 Apr;104(4):612-4. doi: 10.1016/j.rmed.2009.12.014. Epub 2010 Jan 25.

36.

Neutrophils in cystic fibrosis.

Downey DG, Bell SC, Elborn JS.

Thorax. 2009 Jan;64(1):81-8. doi: 10.1136/thx.2007.082388. Review.

PMID:
19103874
37.

The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.

Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS.

Pediatr Pulmonol. 2007 Aug;42(8):729-35.

PMID:
17588254
38.

Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey.

Hester KL, Powell T, Downey DG, Elborn JS, Jarad NA.

J Cyst Fibros. 2007 Jul;6(4):311-3. Epub 2007 Feb 8.

39.

The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis.

Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher B, Edgar J, Bilton D, Elborn JS.

Pediatr Pulmonol. 2007 Mar;42(3):216-20.

PMID:
17238189
40.

Microbial ecology of the cystic fibrosis lung: does microflora type influence microbial loading?

Moore JE, Shaw A, Millar BC, Downey DG, Murphy PG, Elborn JS.

Br J Biomed Sci. 2005;62(4):175-8.

PMID:
16411377
41.

MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?

Downey DG, Kidd TJ, Coulter C, Bell SC.

J Cyst Fibros. 2005 Sep;4(3):205-7.

42.

Reduction in neutrophil elastase concentration by recombinant alphal-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic fibrosis patients.

Moore JE, Shaw A, Millar BC, Martin SL, Murphy PG, Downey DG, Ennis M, Elborn JS.

Br J Biomed Sci. 2004;61(3):146-7. No abstract available.

PMID:
15462261
43.

Safety of sputum induction.

Kelly MG, Downey DG, Ennis M, Elborn JS.

Chest. 2000 Jul;118(1):276. No abstract available.

PMID:
10893400

Supplemental Content

Loading ...
Support Center